Press Releases
Latest
Phase 2b Study Identifies Dose-Response Signals for APPA in Knee Osteoarthritis, with Statistically Significant Benefits on Several Outcomes at the Higher Dose in Patients with Higher Baseline Pain
[PRESSWIRE] London, United Kingdom — 7 November 2026. NBCD A/S and AKL Therapeutics today reported findings from a Phase 2b…
















